CCND1 and breast cancer: Despite a positive association between cyclin D1 protein and CCND1 amplification status, both low nuclear fraction of cyclin D1 and CCND1 amplification were linked to earlier disease recurrence independently of other clinicopathological parameters - hence both factors serve as prognostic markers in endocrine-treated, ER-positive postmenopausal breast cancer.